In less than 36 hours between the evening of Jan. 12 and the morning of Jan. 14, three local life science companies raised a ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

Tune Therapeutics’ co-founders, from left: Akira Matsuno, chief financial officer; Charles Gersbach; and Fyodor Urnov, who also serves on the startup’s scientific advisory board. (Tune Photos ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced a major milestone Sunday — raising $175 million in a Series B funding round to support its ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years. Tune ...

CAMBRIDGE, Mass. - Eterna Therapeutics (NASDAQ:ERNA), a biotechnology company specializing in cell therapies for solid tumors ...

STORY HIGHLIGHTS Tune Therapeutics raised $175 million for disease treatment development. The funding supports hepatitis B clinical trials and research. Tune develops epigenetic treatments ...

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome ...

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New ...

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise ...